YD Bio Limited Ordinary Shares
YDES
Get informed when a big investor buys or sells
+ FollowMarket Cap$162.56M
Close$
$-0.13
104.9% downside
Current Fair Value
104.9% downsideOvervalued by 104.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $162.56 Million |
|---|---|
| Enterprise Value | $156.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | -0.12 |
| Outstanding Shares | 3,409,483 |
Return
| Return on Equity | 104.17% |
|---|---|
| Return on Assets | -21.59% |
| Return on Invested Capital | -24.61% |
Valuation & Multiples
| P/E Ratio | -1.41 |
|---|---|
| PEG | 1.25 |
| Price to Sales | - |
| Price to Book Ratio | -2.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -52.43 |
| Enterprise Value to Net Income | -53 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.24%▲ 0.03% |
|---|---|
| Total Invested | $1.23M▼ 28.83% |
| Investors Holding | 8▼ 2.00% |
ESG Score
No data
About YD Bio Limited Ordinary Shares
4 employees
CEO: Ethan Shen Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of ...